(Q30873309)

English

Intranasal administration of a live non-pathogenic avian H5N1 influenza virus from a virus library confers protective immunity against H5N1 highly pathogenic avian influenza virus infection in mice: comparison of formulations and administration rout

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 June 2017

Intranasal administration of a live non-pathogenic avian H5N1 influenza virus from a virus library confers protective immunity against H5N1 highly pathogenic avian influenza virus infection in mice: comparison of formulations and administration rout (English)

1 reference

Europe PubMed Central

27 June 2017

avian influenza

1 reference

based on heuristic

inferred from title

Yoshihiro Kawaoka

15

object named as

Yoshihiro Kawaoka

1 reference

Europe PubMed Central

27 June 2017

16

object named as

Hiroshi Kida

1 reference

Europe PubMed Central

27 June 2017

Yoshihiro Sakoda

4

object named as

Yoshihiro Sakoda

1 reference

Europe PubMed Central

27 June 2017

Misako Nakayama

9

object named as

Misako Nakayama

1 reference

Europe PubMed Central

27 June 2017

3

object named as

Yasushi Itoh

1 reference

Europe PubMed Central

27 June 2017

13

object named as

Hideaki Ishida

1 reference

Europe PubMed Central

27 June 2017

Masatoshi Okamatsu

11

object named as

Masatoshi Okamatsu

1 reference

Europe PubMed Central

27 June 2017

Kazumasa Ogasawara

17

object named as

Kazumasa Ogasawara

1 reference

Europe PubMed Central

27 June 2017

Hirohito Ishigaki

12

object named as

Hirohito Ishigaki

1 reference

Europe PubMed Central

27 June 2017

8

object named as

Hiroichi Ozaki

1 reference

Europe PubMed Central

27 June 2017

7

object named as

Kosuke Soda

1 reference

Europe PubMed Central

27 June 2017

5

object named as

Tomoya Nagata

1 reference

Europe PubMed Central

27 June 2017

Taichiro Miyake

6

object named as

Taichiro Miyake

1 reference

Europe PubMed Central

27 June 2017

10

object named as

Hitomi Shibuya

1 reference

Europe PubMed Central

27 June 2017

author name string

Yoshitaka Kashima

1

1 reference

Europe PubMed Central

27 June 2017

Mizuho Ikeda

2

1 reference

Europe PubMed Central

27 June 2017

Toshihiro Sawai

14

1 reference

Europe PubMed Central

27 June 2017

language of work or name

0 references

publication date

10 September 2009

1 reference

Europe PubMed Central

27 June 2017

1 reference

Europe PubMed Central

27 June 2017

27

1 reference

Europe PubMed Central

27 June 2017

7402-7408

1 reference

Europe PubMed Central

27 June 2017

52

1 reference

Europe PubMed Central

27 June 2017

Human infection with highly pathogenic H5N1 influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Strategies for developing vaccines against H5N1 influenza A viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

MEASLES IMMUNIZATION WITH KILLED VIRUS VACCINE. SERUM ANTIBODY TITERS AND EXPERIENCE WITH EXPOSURE TO MEASLES EPIDEMIC.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Live attenuated vaccines against influenza; an historical review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Effective immunization with live attenuated influenza A virus can be achieved in early infancy. Pediatric Care Center

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Avian influenza A (H5N1) in 10 patients in Vietnam

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Peptides coupled to the surface of a kind of liposome protect infection of influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1 /80 (H7N7) influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Detection of antibodies to the nonstructural protein (NS1) of influenza A virus allows distinction between vaccinated and infected horses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Genetic analysis of human H2N2 and early H3N2 influenza viruses, 1957-1972: evidence for genetic divergence and multiple reassortment events

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Postreassortment changes in a model system: HA-NA adjustment in an H3N2 avian-human reassortant influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Intranasal administration of drugs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Regulation of airway tight junctions by proinflammatory cytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Class switch recombination and somatic hypermutation in early mouse B cells are mediated by B cell and Toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.089

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.08.089

1 reference

Europe PubMed Central

27 June 2017

1 reference

Europe PubMed Central

27 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30873309&oldid=1858969921"